(This is CNBC Pro's live coverage of Wednesday's analyst calls and Wall Street chatter. Please refresh every 20-30 minutes to view the latest posts.) Tesla and a pharmaceutical giant were among the stocks analysts were talking about on Wednesday.

Goldman Sachs raised its price target on Tesla, but it still sees a a decline for the electric vehicle maker. Barclays also hiked its Eli Lilly target, indicating roughly 10% upside. Check out the latest calls and chatter below.

All times ET. 6:04 a.m.

: Target has 'exceptionally strong merchandising' but missing upside drivers, Piper Sandler says Piper Sandler thinks Target is a safe play for investors with a longer investment horizon. Analyst Peter Keith assumed coverage of the retailer with a neutral rating and $156 price target, suggesting shares can add 5.7% over the next year.

Its shares seem "properly valued" for a retailer with this long-term outlook, he said. "We like TGT's strong omni-channel model and believe the company has exceptionally strong merchandising capabilities. Furthermore, we believe both the 2024 EPS guidance and medium-term EBIT margin target of 6% look reasonable," Keith said in a Wednesday note.

He added, however, that "we don't see a discernable catalyst to push sales/margin above estimates near-term." Keith said Target provides both "best-in-class" merchandising with a strong focus on customer experience in its stores and online, and expects those traits to help revive the company's sales for the rest of .